內科Meadows, Telly A.Telly A.MeadowsBhatt, Deepak L.Deepak L.BhattCannon, Christopher P.Christopher P.CannonGersh, Bernard J.Bernard J.GershRöther, JoachimJoachimRötherGoto, ShinyaShinyaGotoLiau, Chiau-SuongChiau-SuongLiauWilson, Peter W.F.Peter W.F.WilsonSalette, GenevieveGenevieveSaletteSmith, Sidney C.Sidney C.SmithSteg, Ph. GabrielPh. GabrielSteg2012-07-052018-07-112012-07-052018-07-112011http://ntur.lib.ntu.edu.tw//handle/246246/240761OBJECTIVE: To determine whether ethnic-specific differences in the prevalence of cardiovascular risk factors and outcomes exist worldwide among individuals with stable arterial disease. PATIENTS AND METHODS: From December 1, 2003, to June 30, 2004, the prospective, observational REduction of Atherothrombosis for Continued Health (REACH) Registry enrolled 49,602 outpatients with coronary artery disease, cerebrovascular disease, and/or peripheral arterial disease from 7 predefined ethnic/ racial groups: white, Hispanic, East Asian, South Asian, Other Asian, black, and Other (comprising any race distinct from those specified). The baseline demographic and risk factor profiles, medication use, and 2-year cardiovascular outcomes were assessed among these groups. RESULTS: The prevalence of traditional atherothrombotic risk factors varied significantly among the ethnic/racial groups. The use of medical therapies to reduce risk was comparable among all groups. At 2-year follow-up, the rate of cardiovascular death was significantly higher in blacks (6.1%) compared with all other ethnic/racial groups (3.9%; P=.01). Cardiovascular death rates were significantly lower in all 3 Asian ethnic/racial groups (overall, 2.1%) compared with the other groups (4.5%; P <.001). CONCLUSION : The REACH Registry, a large international study of individuals with atherothrombotic disease, documents the important ethnic- specific differences In cardiovascular risk factors and variations in cardiovascular mortality that currently exist worldwide.en-US[SDGs]SDG32,4 thiazolidinedione derivative; acetylsalicylic acid; angiotensin receptor antagonist; beta adrenergic receptor blocking agent; biguanide derivative; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; diuretic agent; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; nitrate; nonsteroid antiinflammatory agent; sulfonylurea; adult; aged; article; Asian; body mass; cardiovascular risk; Caucasian; cerebrovascular disease; cigarette smoking; controlled study; coronary artery disease; demography; diabetes mellitus; drug use; employment status; ethnic difference; female; follow up; Hispanic; human; hyperlipidemia; hypertension; major clinical study; male; mortality; Negro; peripheral occlusive artery disease; prospective study; risk assessment; risk reduction10.4065/mcp.2011.0010